Literature DB >> 23416893

Poly(ADP-ribose) signaling in cell death.

László Virág1, Agnieszka Robaszkiewicz, Jose Manuel Rodriguez-Vargas, Francisco Javier Oliver.   

Abstract

Poly(ADP-ribosyl)ation (PARylation) is a reversible protein modification carried out by the concerted actions of poly(ADP-ribose) polymerase (PARP) enzymes and poly(ADP-ribose) (PAR) decomposing enzymes such as PAR glycohydrolase (PARG) and ADP-ribosyl hydrolase 3 (ARH3). Reversible PARylation is a pleiotropic regulator of various cellular functions but uncontrolled PARP activation may also lead to cell death. The cellular demise pathway mediated by PARylation in oxidatively stressed cells has been described almost thirty years ago. However, the underlying molecular mechanisms have only begun to emerge relatively recently. PARylation has been implicated in necroptosis, autophagic cell death but its role in extrinsic and intrinsic apoptosis appears to be less predominant and depends largely on the cellular model used. Currently, three major pathways have been made responsible for PARP-mediated necroptotic cell death: (1) compromised cellular energetics mainly due to depletion of NAD, the substrate of PARPs; (2) PAR mediated translocation of apoptosis inducing factor (AIF) from mitochondria to nucleus (parthanatos) and (3) a mostly elusive crosstalk between PARylation and cell death/survival kinases and phosphatases. Here we review how these PARP-mediated necroptotic pathways are intertwined, how PARylation may contribute to extrinsic and intrinsic apoptosis and discuss recent developments on the role of PARylation in autophagy and autophagic cell death.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Autophagy; Cell death; Necroptosis; Necrosis; Oxidative stress; Poly(ADP-ribose) glycohydrolase; Poly(ADP-ribose) polymerase

Mesh:

Substances:

Year:  2013        PMID: 23416893     DOI: 10.1016/j.mam.2013.01.007

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  88 in total

1.  Up-regulation of the chemo-attractive receptor ChemR23 and occurrence of apoptosis in human chondrocytes isolated from fractured calcaneal osteochondral fragments.

Authors:  Paola Sena; Giuseppe Manfredini; Marta Benincasa; Francesco Mariani; Alberto Smargiassi; Fabio Catani; Carla Palumbo
Journal:  J Anat       Date:  2014-04-01       Impact factor: 2.610

2.  Suppressing PARylation by 2',5'-oligoadenylate synthetase 1 inhibits DNA damage-induced cell death.

Authors:  Anna A Kondratova; HyeonJoo Cheon; Beihua Dong; Elise G Holvey-Bates; Metis Hasipek; Irina Taran; Christina Gaughan; Babal K Jha; Robert H Silverman; George R Stark
Journal:  EMBO J       Date:  2020-04-23       Impact factor: 11.598

3.  Regulation of mitochondrial poly(ADP-Ribose) polymerase activation by the β-adrenoceptor/cAMP/protein kinase A axis during oxidative stress.

Authors:  Attila Brunyanszki; Gabor Olah; Ciro Coletta; Bartosz Szczesny; Csaba Szabo
Journal:  Mol Pharmacol       Date:  2014-07-28       Impact factor: 4.436

Review 4.  Regulated necrosis: the expanding network of non-apoptotic cell death pathways.

Authors:  Tom Vanden Berghe; Andreas Linkermann; Sandrine Jouan-Lanhouet; Henning Walczak; Peter Vandenabeele
Journal:  Nat Rev Mol Cell Biol       Date:  2014-02       Impact factor: 94.444

5.  Intervention timing and effect of PJ34 on astrocytes during oxygen-glucose deprivation/reperfusion and cell death pathways.

Authors:  Chuan Cai; Rui Zhang; Qiao-Ying Huang; Xu Cao; Liang-Yu Zou; Xiao-Fan Chu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

Review 6.  PARP-1 and its associated nucleases in DNA damage response.

Authors:  Yijie Wang; Weibo Luo; Yingfei Wang
Journal:  DNA Repair (Amst)       Date:  2019-07-08

Review 7.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

8.  Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.

Authors:  Sevil Korkmaz-Icöz; Bartosz Szczesny; Michela Marcatti; Shiliang Li; Mihály Ruppert; Felix Lasitschka; Sivakkanan Loganathan; Csaba Szabó; Gábor Szabó
Journal:  Br J Pharmacol       Date:  2017-10-02       Impact factor: 8.739

9.  Modulation of poly(ADP-ribose) polymerase-1 (PARP-1)-mediated oxidative cell injury by ring finger protein 146 (RNF146) in cardiac myocytes.

Authors:  Domokos Gerö; Petra Szoleczky; Athanasia Chatzianastasiou; Andreas Papapetropoulos; Csaba Szabo
Journal:  Mol Med       Date:  2014-07-31       Impact factor: 6.354

10.  Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.

Authors:  Lianne E Rotin; Neil MacLean; Ahmed Aman; Marcela Gronda; Feng-Hsu Lin; Rose Hurren; XiaoMing Wang; Jeffrey L Wrana; Alessandro Datti; Rima Al-Awar; Mark D Minden; Aaron D Schimmer
Journal:  Haematologica       Date:  2016-09-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.